Hachitanda Y, Nakagawara A, Nagoshi M, Tsuneyoshi M
Second Department of Pathology, Kyushu University School of Medicine, Fukuoka, Japan.
Acta Pathol Jpn. 1992 Sep;42(9):639-44. doi: 10.1111/j.1440-1827.1992.tb03044.x.
Data on 43 neuroblastic tumors (30 neuroblastomas and 13 ganglioneuroblastomas) obtained from 22 untreated and 21 pretreated children, were analyzed to determine the correlation between N-myc oncogene amplification and immunohistochemically identified S-100 protein positivity. Sixteen patients in whom the tumor showed significant amplification of N-myc (more than ten copies) died, irrespective of S-100 protein positivity and other conventional factors. Among 27 patients with low amplification of N-myc (less than ten copies), the estimated progression-free survival for those whose tumors had numerous S-100 protein-positive cells (P group), and few or no positive cells (N group) was 75% and 17%, respectively (p < 0.0001). Thus, in addition to N-myc oncogene amplification as a reliable indicator of outcome, S-100 protein positivity should be useful for prediction of prognosis in children with neuroblastic tumors showing low amplification of N-myc. Correlations among these results and other clinical factors are briefly discussed.
对从22名未经治疗和21名经预处理的儿童中获得的43例神经母细胞瘤（30例神经母细胞瘤和13例神经节神经母细胞瘤）的数据进行分析，以确定N - myc癌基因扩增与免疫组织化学鉴定的S - 100蛋白阳性之间的相关性。16例肿瘤显示N - myc显著扩增（超过10个拷贝）的患者死亡，无论S - 100蛋白阳性情况及其他传统因素如何。在27例N - myc低扩增（少于10个拷贝）的患者中，肿瘤有大量S - 100蛋白阳性细胞的患者（P组）和少量或无阳性细胞的患者（N组）的无进展生存率估计分别为75%和17%（p < 0.0001）。因此，除了N - myc癌基因扩增作为预后的可靠指标外，S - 100蛋白阳性对于预测N - myc低扩增的神经母细胞瘤患儿的预后应该是有用的。简要讨论了这些结果与其他临床因素之间的相关性。
